Dysfunctional high-density lipoprotein: Not only quantity but first of all quality?

Archives of Medical Science

Volumn 11, Issue 1, 2015, Pages 230-231

  Agouridis, Aris P ^a,b   Banach, Maciej ^c   Mikhailidis, Dimitri P ^d  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; C REACTIVE PROTEIN; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; TORCETRAPIB;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CHRONIC INFLAMMATION; COMMON CAROTID ARTERY; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; GENETICS; HUMAN; LETTER; PLEIOTROPY; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SOUTH ASIAN;

EID: 84925018404     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.49816     Document Type: Letter

References (13)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
2. Rizzo M, Otvos J, Nikolic D, Montalto G, Toth PP, Banach M. Subfractions and subpopulations of HDL: an update. Curr Med Chem 2014; 21: 2881-91.
3. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 370-8.
4. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.
5. Toth PP, Barylski M, Nikolic D, Rizzo M, Montalto G, Banach M. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab 2014; 28: 353-68.
6. Florentin M, Kostapanos MS, Kei A, Elisaf M. Emerging drugs for hyperlipidaemia: an update. Expert Opin Emerg Drugs 2014; 19: 471-88.
7. Dodani S, Dong L, Guirgis FW, Reddy ST. Carotid intima media thickness and low high-density lipoprotein (HDL) in South Asian immigrants: could dysfunctional HDL be the missing link? Arch Med Sci 2014; 10: 870-9.
8. Gomaraschi M, Adorni MP, Banach M, Bernini F, Franceschini G, Calabresi L. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function. Handb Exp Pharmacol 2015; 224: 593-615.
9. Dragan S, Serban C, Banach M. Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents? Curr Med Chem 2014; 21: 2927-46.
10. Banach M, Rysz J, Rizzo M, et al. Investigating dysfunctional-HDL in selected groups of patients at high risk of cardiovascular events (DYS-HDL study)-Protocol and organization. Atherosclerosis 2014; 235: e171-2.
11. Serban C, Muntean D, Mikhailidis DP, Toth PP, Banach M. Dysfunctional HDL: the journey from savior to slayer. Clin Lipidol 2014; 9: 49-59.
12. Kucera M, Oravec S, Hirnerova E, et al. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study. Angiology 2014; 65: 794-9.
13. Al-Zakwani I, Sulaiman K, Al-Rasadi K, Mikhailidis DP. Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. Curr Med Res Opin 2011; 27: 879-85.